NYSE · MANE
Veradermics, Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MANE: Nov 10, 2026
Veradermics, Incorporated Common Stock is estimated to report earnings on 11/10/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.59.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.59 | $-0.59 | $-0.59 | 1 |
| Dec 2026 | $-0.64 | $-0.64 | $-0.64 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · RTTNews · Zacks- The Motley Fool · Oct 25, 9:20 AM EDTWhy This Hair Restoration Biotech's Shares Are SoaringThe company just released positive phase 3 results for VDPHL01, an oral extended-release formulation of minoxidil.
- MarketBeat · Oct 19, 1:02 PM EDTVeradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth ResultsVeradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss. The randomized, double-blind, placebo-controlled
- RTTNews · Oct 19, 12:53 AM EDTVeradermics To Review Phase 3 Study 304 Results For VDPHL01 In Male Pattern Hair Loss; Stock Up(RTTNews) – Veradermics, Inc. (MANE), a late-stage biopharmaceutical company focused on therapies for pattern hair loss, announced it will review results from Part A of a Phase 3 clinical trial (Study 304) evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. The c
- RTTNews · Oct 9, 6:29 AM EDTBiotech Stocks At 52-Week Highs – PCRX +44% On Acquisition News; MANE+14%, HAE+17%, CON, HSTM(RTTNews) – The following biotech stocks reached a 52-week high on October 8, 2026, driven by catalysts such as reports of an upcoming acquisition or upcoming financial reports.
- RTTNews · Jul 18, 1:19 AM EDTWeekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data(RTTNews) – This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks.
- RTTNews · Jul 15, 11:41 PM EDTTop Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data(RTTNews) – Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy, and Veradermics after reporting positiv
- MarketBeat · Jul 15, 10:04 AM EDTVeradermics Hair Loss Pill Shows Strong Phase II Signal in WomenVeradermics (NYSE:MANE) said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment. Chief Executive Officer Dr.
- Zacks · Jun 24, 9:55 AM EDTCan Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- The Motley Fool · May 14, 2:57 PM EDTThis Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPOSiren initiated a new position by acquiring 1,505,374 shares of Veradermics; the estimated transaction value is $75.94 million based on quarterly average pricing.
- Fintel · May 14, 3:17 AM EDTVeradermics (MANE) Price Target Increased by 39.48% to 128.52The average one-year price target for Veradermics (NYSE:MANE) has been revised to $128.52 / share. This is an increase of 39.48% from the prior estimate of $92.14 dated April 25, 2026. The price target is an average of many targets provided by analysts. The la
- RTTNews · Apr 30, 9:47 AM EDTWeekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA(RTTNews) – This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic areas, including Type 1 Diabetes, Male Pattern Hair Loss, and Hereditary angioedema.
- Fintel · Apr 29, 10:03 AM EDTVeradermics (MANE) Price Target Increased by 15.32% to 92.14The average one-year price target for Veradermics (NYSE:MANE) has been revised to $92.14 / share. This is an increase of 15.32% from the prior estimate of $79.90 dated April 12, 2026. The price target is an average of many targets provided by analysts. The lat
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Veradermics, Incorporated from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.